BioSpace News Archive

Cardiovascular disease, particularly coronary heart disease, remains the No. 1 disease killer and continues to rise in the US and the world despite record numbers of statins being prescribed year after year.

System leverages artificial intelligence and shared decision-making to improve patient care at a low financial cost

Abpro eligible to receive up to $4 billion, including $60 million in near-term R&D funding, plus potential milestones and royalties

NOXXON Pharma N.V. announced that the company will present the latest safety, survival and more mature clinical data in patients treated with the CXCL12 inhibitor NOX-A12 in combination with Merck & Co./MSD’s PD-1 inhibitor Keytruda® in metastatic, microsatellite stable pancreatic and colorectal cancer patients.

Forty-two percent of all deaths in the United States are related to cardiovascular disease.

Shares of Bristol-Myers Squibb took a hit Wednesday after two large stakeholders in the company objected to the pending acquisition of Celgene. Wellington and Starboard Value have both publicly voiced opposition to the deal.

Guardant Health announced positive results from its NILE study, a head-to-head trial of its Guardant360 compared to standard-of-care tissue testing in first-line advanced non-small cell lung cancer (NSCLC).

Shares of Maryland-based Novavax are down 66 percent in morning trading after the company announced its respiratory syncytial virus (RSV) vaccine called ResVax failed to hit its primary endpoint in a Phase III trial.

There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.

While real estate developers are building new spaces for life science companies in the Bay Area, startups are struggling to find space.